Navigation Links
New Study Shows Tapentadol Extended Release (ER) May Significantly Reduce Average Pain Intensity for Diabetic Patients Suffering From Painful Peripheral Neuropathy
Date:1/28/2011

hase, during which all patients were titrated to their individually optimal tapentadol ER dose (100–250 mg two times per day), followed by a 12-week, double-blind maintenance phase, during which patients were randomized either to continue taking tapentadol ER (at their optimal dose) or to receive placebo.

The primary efficacy endpoint of the study was to measure the change in average pain intensity, as determined by a twice-daily, 11-point pain rating scale or numerical rating scale (NRS; 0='no pain,' 10='pain as bad as you can imagine'), from the point of randomization.  Safety was also assessed throughout the study.

At the start of the 3-week, open-label phase, the majority of patients (79.4%) reported severe pain (greater than or equal to 6 on the 11-point NRS) with a mean pain intensity of 7.3. By the end of the open-label phase, the mean pain intensity was reduced to 3.5. Following randomization, over the double-blind treatment phase to week 12, pain increased in the placebo group (as demonstrated by the average change in pain intensity of 1.4), while in the tapentadol ER group, pain relief was maintained, as indicated by the change in pain intensity value of 0.0. The mean difference between the tapentadol ER and placebo groups in the change in average pain intensity was -1.3 on the 11-point NRS (95 percent CI; p<0.001, tapentadol ER vs. placebo).  Researchers observed statistically significant differences in favor of tapentadol ER using all imputation methods.

In a secondary analysis, where rates of those who responded to treatment were calculated, 53.6 percent of patients receiving tapentadol ER and 42.2 percent of patients receiving placebo (p=0.017) experienced at least a 30 percent improvement in pain intensity measured from pre-titration to week 12 of the double-blind treatment period.

The patient's global impression of change (PGIC) provided an additional secondary analysis where patients evaluated on a 7-
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
2. US Army Study Shows STB Lifesaving Technologys® FAST® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
3. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
4. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
5. Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
6. R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia
7. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
8. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump® and ResQPOD® CPR Devices
9. CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions
10. New Study on HIV/AIDS Redefines the Size, Scale, and Scope of Epidemic
11. Groundbreaking Study Showed Bayers Advantage Multi® for Dogs (imidacloprid + moxidectin) Topical Solution was the only Heartworm Preventive Tested That Demonstrated 100 Percent Efficacy against the Challenging MP3 Strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...  Decision Resources Group finds that the laparoscopic device ... will increase to a value of over $4.3 billion ... in the large direct energy device market. In particular, ... due to the advantages they offer and as new ... Decision Resources Group,s coverage of the U.S. laparoscopic device ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... 17, 2014 Revenue and earnings above ... research and development In the past 2013/14 fiscal ... two percent to EUR 4.287 billion (last year: EUR 4.190 ... percent to EUR 360 million. "Overall, 2013/14 was a successful ... Kaschke , President and CEO of Carl Zeiss AG. "Thanks ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... SAN DIEGO , April 27 ResMed Inc. (NYSE: RMD ) ... , , ... Boston on May 4, 2010 ; Jefferies Global Life Sciences Conference ... ; William Blair Growth Stock Conference at the Four Seasons in Chicago ...
... 27 Volcano Corporation (Nasdaq: VOLC ), ... guidance tools designed to enhance the diagnosis and treatment ... it has entered into a distribution agreement with AngioScore ... indications in Japan . This is the first ...
Cached Medicine Technology:ResMed Inc. to Present at Upcoming Conferences 2Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 2Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 3Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 4
(Date:12/19/2014)... Colorado (PRWEB) December 20, 2014 It’s very ... travel is something that is put to the wayside until ... who still have that travel “itch” and that burning desire ... Montrose accommodates families on their journey to Telluride with a ... get visitors to and from the resort, and ensure that ...
(Date:12/19/2014)... 19, 2014 The Plantrician ... developing educational events, tools and resources for healthcare ... School , the world’s leading online cooking school, ... human being needs: Culinary Rx. As an online ... Culinary Rx, scheduled for debut spring 2015, will ...
(Date:12/19/2014)... These vanadium reserves are mostly found in China, ... of vanadium were produced globally in 2013, up 11% ... 6.7% AAGR during the period from 2001 to 2013, ... largest consumer, accounted for more than 90% of total ... the chemical industry. , View Full Report at ...
(Date:12/19/2014)... research warns parents that buying an older car for their teens ... teen drivers killed in the United States between 2008 and 2012 ... often lacked important safety features that are available on newer cars, ... crashes were in cars at least six years old, 34 percent ... in cars 11 to 15 years old, and 17 percent were ...
(Date:12/19/2014)... drug users who also use cocaine and amphetamines have ... users, a new study finds. "We know that ... attempt and completed suicide," Didier Jutras-Aswad, a psychiatry professor ... news release. "However, there are many different profiles of ... users were actually more likely to attempt suicide." ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2
... , FRIDAY, Sept. 16 (HealthDay News) -- People ... clotting and inflammation have a lower five-year survival rate ... findings should be used to better treat and ensure ... said the research team from Duke University Medical Center ...
... GALVESTON, September 16, 2011 Researchers have shown for the ... cells by binding to and rendering inert protein p53, a ... of Texas Medical Branch may lead to treatments for a ... and appears in the current print issue of the ...
... has awarded $11.3 million to Case Western Reserve University ... for research on gastrointestinal cancers. The funding designates the ... in Gastrointestinal (GI) Cancers recognition extended to just ... is the primary affiliate of Case Western Reserve and ...
... WINSTON-SALEM, N.C. Sept. 16, 2011 A study ... colleagues suggests that a high intake of calcium causes ... absorbers of the mineral. "High dietary intake of ... the explanation for this observation has been elusive," said ...
... (USC) epidemiologists suggests that a high intake of calcium ... good absorbers of the mineral. "High dietary intake ... and this study suggests that these associations are likely ... professor of preventive medicine at the Keck School of ...
... highlight Pain Awareness Month in September, The ... interdisciplinary organization devoted to the field of aging is ... for seniors. Paired with its other recent research findings, ... advances in pain prevention, treatment, and management may improve care ...
Cached Medicine News:Health News:Gene Variant May Raise Death Risk After Heart Bypass 2Health News:Researchers identify potential molecular target to prevent growth of cancer cells 2Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 2Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 3Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 4Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 5Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 6Health News:Genetics may explain why calcium increases risk for prostate cancer 2Health News:Genetics may predict why calcium increases risk for prostate cancer 2Health News:GSA sets focus on optimizing older adults' pain care 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and ... sample inoculation. With these slides, perform QC ... ,Laboratories enhance their education and training programs ... and interpretation, all on one slide! KWIK-QC ...
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
Each slide contains a high yield of concentrated C. parvum oocysts within the positive control well. A negative control well is also included....
Medicine Products: